| Document |
Document Title |
|
WO/2024/091676A1 |
Embodiments of the instant disclosure relate to novel compositions and methods for generating thymic cells. In some embodiments, thymic cells can be differentiated from pluripotent stem cells (PSC), anterior primitive streak (APS) cells,...
|
|
WO/2024/091495A1 |
Among other things, the present disclosure provides compositions, e.g., recombinant adeno- associated virus (rAAV) vectors, comprising, e.g., an inhibitory nucleic acid (e.g., a miRNA) and/or a therapeutic nucleic acid sequence encoding ...
|
|
WO/2024/090491A1 |
The present invention provides a cell-membrane-permeable peptide for conjugation, represented by general formula (P1) [in general formula (P1): R101 is a 2-pyridyl group that may have a substituent; A1 is a cell-membrane-permeable peptid...
|
|
WO/2024/087423A1 |
An mRNA drug, which reduces expression in the liver after being delivered to the body, and a preparation method therefor. The preparation method comprises: establishing double 3'UTR in a target mRNA, and introducing a miR-122 binding sit...
|
|
WO/2024/087860A1 |
The present invention relates to a method for obtaining high-purity and high-stability recombinant human albumin by adding medium- and long-chain fatty acid ligands and removing a protein having charge heterogeneity by means of anion or/...
|
|
WO/2024/089293A1 |
The present invention discloses a method of therapeutically treating cancer, in particular CRC (colorectal cancer), or of reducing the risk of cancer in particular CRC, disease progression in a patient comprising expressing miR-326 in th...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/091545A1 |
Nucleic acid error suppression is provided. In various embodiments, DNA is extracted from a collection of plasma samples. A sequence library with duplex adapters is prepared. The library is prepared by ligating a duplex adapter having a ...
|
|
WO/2024/086999A1 |
Provided is a method for regulating migrasome formation by a cell and/or migrasome-mediated biological process, comprising regulating the amount and/or function of PIP2 related pathway in said cell.
|
|
WO/2024/091286A1 |
A composition for treating Huntington's disease (HD) by reducing endogenous Huntingtin (HTT) levels in a target includes an ASO comprising an ASO sequence selected from SEQ ID NOs:18 to 86, and a carrier peptide comprising a peptide sequ...
|
|
WO/2024/088190A1 |
Provided is an RNA inhibitor for inhibiting LPA gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor is formed by base pairing of a sense strand and an antisense strand having a chain length of 15-30, and the ...
|
|
WO/2024/086929A1 |
Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol% ...
|
|
WO/2024/089124A1 |
The invention relates to a catechol O-methyltransferase (COMT) inhibitor for use in the treatment of osteoarthritis, the inhibitor being intended to slow down the progression of osteoarthritis and reduce osteoarthritis pain, as well as t...
|
|
WO/2024/091804A1 |
Certain embodiments of the disclosure are related to, inter alia, mutant and/or modified Bacillus cells (strains) comprising enhanced protein productivity phenotypes, mutant and/or modified cells comprising enhanced/increased ilvE messen...
|
|
WO/2024/090458A1 |
The purpose of the present invention is to provide: a substance which has an activity of binding to an inhibitory KIR to inhibit the cytotoxic activity of an NK cell and is useful for allogeneic technologies associated with organ transpl...
|
|
WO/2024/091949A1 |
The disclosure provides methods and systems for sample screening which may involve screening samples in presence and/or absence of effectors (e.g., encoded effector/compound libraries) for their potential effects on the sample or a targe...
|
|
WO/2024/087539A1 |
An enhanced StayGold yellow fluorescent protein and the use thereof, which relate to the technical field of recombinant proteins. With regard to the enhanced StayGold yellow fluorescent protein, the amino acid sequence of StayGold compri...
|
|
WO/2024/092164A1 |
Disclosed herein include novel blood-brain barrier (BBB)-crossing receptors on the BBB interface, targeting peptides and derivatives thereof capable of binding to the novel receptors, and related methods of using the receptors to increas...
|
|
WO/2023/214405A9 |
Methods of predicting clinical outcome in a subject suffering from cancer, detecting non-liver cancer in a subject, and methods of treating or preventing cancer or cancer-associated cachexia are provided. Synthetic lipid nanoparticles en...
|
|
WO/2024/088087A1 |
The present invention relates to the field of medical biology, and specifically to expression of a human papillomavirus (HPV) 68 L1 protein, and virus-like particles (VLPs) and a preparation method therefor. The amino acid sequence of th...
|
|
WO/2024/092032A1 |
High-performance promoters, and other high-performance components, for the construction of CRISPR-based synthetic gene regulatory networks (GRNs) and methods for engineering and using the promoters and components. Activatable promoters w...
|
|
WO/2024/086925A1 |
Disclosed herein are cell-free protein synthesis systems, reaction mixtures for the same, and methods for preparing a protein of interest.
|
|
WO/2024/088384A1 |
Provided in the present invention are a gene editor for disease treatment and a nucleic acid pharmaceutical composition for an anti-fibrosis inhibitor. Specifically, the pharmaceutical composition contains: (a) a first active ingredient,...
|
|
WO/2024/086619A2 |
The present disclosure provides for a nucleic acids encoding for a transforming growth factor inhibitor and IL-12. Further provided herein are nucleic acids encoding for chemokine receptor CXCR3. Additionally described herein are oncolyt...
|
|
WO/2024/084059A1 |
Methods and products for discovering disease biomarkers and diagnosing disease are provided. RNA or cDNA samples are typically dominated by sequences from highly expressed genes which can negatively affect analysis of the samples. The pr...
|
|
WO/2024/082681A1 |
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furtherm...
|
|
WO/2024/086596A1 |
Provided herein are improved methods, compositions, and systems for editing genomic DNA, including editing genomic DNA by inserting long DNA sequences into genomic DNA.
|
|
WO/2024/083870A1 |
There is provided an Aβ peptide binding polypeptide, which comprises an amino acid sequence selected from i) and ii), wherein: i) is SEQ ID NO:1 – [LINK] – SEQ ID NO:2; ii) is SEQ ID NO:3 – [LINK] – SEQ ID NO:4; and [LINK] is a ...
|
|
WO/2024/086713A1 |
The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
|
|
WO/2024/082060A1 |
The present disclosure provides trivalent and trispecific antibody constructs capable of binding two different antigens on one or more cytotoxic effector cell(s) and a tumor-associated antigen (TAA) on a tumor cell. Pharmaceutical compos...
|
|
WO/2024/086848A2 |
The present invention generally relates to compositions comprising a CRISPR based regulatory element comprising a barcode sequence that serves as a binding site for a Cas9/gRNA molecule and which alters expression of a downstream gene wh...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
|
WO/2024/085079A1 |
[Problem] SMN2 gene located in the vicinity of SMN1 gene is different from the SMN1 gene by only 5 bases. Thus, in order to perform an SMA screening test, it was necessary to establish a test system that can detect the SMN1 gene specific...
|
|
WO/2024/015877A9 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these cap...
|
|
WO/2024/084785A1 |
The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine. Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus,...
|
|
WO/2024/084516A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure...
|
|
WO/2024/086352A2 |
Among other things, the present disclosure provides compositions, e.g., isolated nucleic acids, vectors, and recombinant adeno-associated viruses (rAAVs), comprising a nucleic acid sequence encoding a PRPF31 polypeptide. In some embodime...
|
|
WO/2024/086530A1 |
Described herein are chocolate compositions comprising sweet proteins, such as sweet polypeptides (e.g., brazzein, brazzein-53, brazzein-54, or a combination of brazzein-53 and brazzein-54), and method of producing the same.
|
|
WO/2024/084441A1 |
The present disclosure provides methods, compositions, and kits for the treatment or prevention of an HIV infection in a human having or at risk of having HIV, comprising the combination of the HTI immunogen and at least one stable solub...
|
|
WO/2024/085674A1 |
The present invention relates to a fusion protein containing a CAS protein and a bacterial toxin, and a use thereof. A fusion protein, a polypeptide thereof, and a CRISPR-Cas system including same according to the present invention allow...
|
|
WO/2024/085671A1 |
The present application relates to a mutant ribonuclease activity regulating protein and a method for producing L-valine using same.
|
|
WO/2024/084394A1 |
Compounds and methods are provided for facilitating delivery of an oligonucleotide, for example, into a nucleus and/or cytosol of a cell.
|
|
WO/2024/084520A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/086650A1 |
SnRNA systems comprising RNA binding sequences for RNA editing are disclosed herein.
|
|
WO/2024/085533A1 |
The present invention pertains to: a composition for improving the efficiency of introducing vectors into cells by using lunasin; and a method for introducing vectors into cells with high efficiency by using said composition.
|
|
WO/2024/086342A1 |
The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesic...
|
|
WO/2024/082003A1 |
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of...
|
|
WO/2024/085182A1 |
The present invention addresses the problem of providing a novel method for treating T cell tumor, whereby it becomes possible to induce the cell damage of a tumor cell and which is less likely to cause immunodeficiency. According to t...
|
|
WO/2024/086586A2 |
The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject.
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
